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Abstract Large gemistocytic cells are well-known ele-
ments of glial tumors. Recently, miniature gemistocytic
cells and neoplastic glial fibrillary acidic protein (GFAP)-
positive oligodendroglial cells, which are regularly seen
in oligodendrogliomas, have been termed “transitional
cells”. The proliferative activity of the gemistocytic cell
types and the GFAP-positive (gliofibrillary) oligodendro-
cytes was determined in eight astrocytomas, seven gemis-
tocytic astrocytomas, eight glioblastomas, two monstro-
cellular glioblastomas, seven oligodendrogliomas and
three mixed oligo-astrocytomas by immunohistochemical
staining of the proliferation marker MIB-1 in combination
with immunostaining for GFAP. Both large gemistocytic
cells and the transitional cells showed cytoplasmic GFAP-
positive staining. Neither in the classic gemistocytes nor
in the minigemistocytes nuclear immunostaining for the
MIB-1 antibody was observed. In contrast, MIB-1 stain-
ing was seen in the gliofibrillary oligodendrocytes. It is
concluded that both large and miniature gemistocytic cell
types contrast with gliofibrillary oligodendrocytes by
their inability to proliferate.
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Introduction
In 1904 Franz Nissl [17] described a subset of astrocytic
cells which were encountered under pathological condi-
tions and were characterized by voluminous, homoge-
neous, milk-like cytoplasm with plump cell processes and
an eccentric nucleus. These cells were referred to as
gemästete Glia (fattened glia). In the English language
this term was translated in “gemistocytes”. These cells
were not only encountered in reactive processes, but also
in glial tumors. Moreover, some gliomas seemed to be en-
tirely composed of these cells (gemistocytic astrocytomas
or gemistocytomas). Gemistocytes were also regularly
seen as a minor constituent of oligodendrogliomas.
Smaller gemistocytic cells that were found in oligoden-
droglial tumors in particular were reappraised after the in-
troduction of the immunohistochemical stain for glial fib-
rillary acidic protein (GFAP) [7, 16, 26, 27], and were
lumped together with gliofibrillary (or GFAP-positive)
oligodendrocytes (GFOCs) and called transitional cells
[7]. Interrelationships between the transitional cells and
the classic gemistocytes have been suggested based on
immunological and ultrastructural similarities [7, 11, 12].
It has been shown that the presence of classic gemisto-
cytes in astrocytomas and oligodendrogliomas is a prognos-
tically ominous sign [5, 10, 13, 22]. Although this finding
might suggest high proliferation of gemistocytes, in vivo
thymidine incorporation studies have shown that gemisto-
cytes are quiescent cells [8, 9]. The proliferative activity of
the transitional cells has not been studied previously.
The aim of the present study was to investigate
whether classic gemistocytes and transitional cells belong
to the proliferative cell pool in gliomas. To this end, anti-
bodies against the proliferation marker MIB-1 and GFAP
were simultaneously used on formalin-fixed paraffin-em-
bedded material of 35 glial neoplasms in which these
GFAP-positive cells were seen.
Materials and methods
Clinical data
The formalin-fixed paraffin-embedded tissue samples of 15 astro-
cytomas (7 of which were gemistocytic astrocytomas), 7 oligoden-
drogliomas, 3 mixed astro-oligodendrogliomas and 10 glioblas-
tomas (including 2 monstrocellular glioblastomas) were taken
from the files of the Department of Pathology of the University
Hospital Rotterdam-Dijkzigt (Rotterdam, The Netherlands) (Table
1). In addition, two cases of reactive gliosis were retrieved. No
stereotactic biopsy material was included in this study.
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Grading of the astrocytomas and mixed gliomas was done ac-
cording to the WHO guidelines, and to the St.Anne-Mayo scheme
for astrocytic neoplasms [3]. The oligodendrogliomas were graded
according to the WHO guidelines and to the recently developed
scheme by Smith et al. [24]. The ages of the patients at surgery
ranged between 22 and 76 years. All biopsies were performed be-
fore additional radiotherapy was given. None of the patients had
been treated with chemotherapy prior to biopsy.
GFAP/MIB-1 double staining
Paraffin sections (5 µm thick) were cut and mounted on 3-amino-
propyltriethoxisilane-coated slides (Sigma, St. Louis, Mo.). After
deparaffinization and rehydration, endogenous peroxidase was
blocked with 3% H2O2 in methanol. The sections were preincu-
bated with normal goat serum (Dako, The Netherlands), diluted
1:10 in bovine serum albumin (BSA) [5% in phosphate-buffered
saline (PBS), pH 7.4, for 15 min at room temperature (RT)] and
subsequently with anti-GFAP antibody (Dako, Copenhagen, Den-
mark; rabbit polyclonal 1:200 in BSA 5%) for 1 h at RT. After
rinsing in PBS, the sections were incubated with biotinylated goat
anti-rabbit antibody (Dako, The Netherlands), diluted 1:400 in
PBS, for 30 min, streptavidin-biotin-alkaline phosphatase complex
(Dako, The Netherlands) for 30 min and substrate for alkaline
phosphatase (Vector Kit). The sections were rinsed three times in
PBS between each incubation step.
For MIB-1 staining an antigen retrieval procedure [23] was
necessary. The reaction was optimized by placing the sections in a
plastic box containing 200 ml 0.01 M citric acid monohydrate
(Merck, Germany) adjusted to pH 6.0 with NaOH, and heating in
a microwave oven (Miele M696) for 3 × 5 min at 700 W. After
preincubation (15 min) with normal goat serum, diluted 1:10 in
100
Table 1 Summary of cases in-
vestigated. The MIB-1 range is
given as % positive nuclei/5
high-power fields. [0 absent, 
+ small numbers in some fields,
++ intermediate numbers,
+++ large numbers seen in




strous cells, gem. astro gemis-
tocytic astrocytoma, gbm
glioblastoma]
Despite large regional differ-
ences in percentage of positive
nuclei, the MIB-1 labeling in-
dex roughly correlated with 




Grade Grade MIB-1 gem mini GFOC mons
(WHO) Daumas- range
Duporta)
1. Astrocytoma 2 2 0– 5 0 0 0 0
2. Gem. astro 3 2 5–20 +++ + 0 0
3– 8. Gem. astro 3 3 5–40 +++ ++ 0 0
9. Astrocytoma 3 3 5–10 0 0 0 0
10. Astrocytoma 3 3 5–10 0 + 0 0
11. Astrocytoma 3 3 5–20 + + 0 0
12. Astrocytoma 3 3 5–25 + 0 0 0
13. Astrocytoma 3 3 5–30 + ++ 0 0
14. Astrocytoma 3 3 5–30 + + 0 0
15. Astrocytoma 4 4 20–40 ++ ++ 0 0
16–18. gbm 5–50 ++ 0 0 0
19–20. gbm 5–45 ++ + 0 ++
21–25. gbm 40–50 0 0 0 0
26. Oligo-astrocytoma 2 2 10–30 + + + 0
27. Oligo-astrocytoma 2 2 10–40 + ++ + 0
28. Oligo-astrocytoma 3 3 20–50 ++ + 0 0
Grade Grade
(WHO) (Smithb)
29. Oligodendroglioma 2 2 0– 5 0 0 0 0
30. Oligodendroglioma 2 2 0– 5 + +++ ++ 0
31. Oligodendroglioma 3 3 5–10 + +++ + 0
32. Oligodendroglioma 3 3 10–20 0 + ++ 0
33. Oligodendroglioma 3 3 10–30 0 0 0 0
34. Oligodendroglioma 3 3 20–40 + + + 0
35. Oligodendroglioma 3 3 20–40 + + + 0
Fig.1 Gemistocytic astrocytoma grade 3 (case 2). The large
gemistocytic cells are invariably negative for MIB-1, while nuclei
of interspersed neoplastic glial cells are positive. Glial fibrillary
acidic protein (GFAP)/MIB-1 double labeling, × 150
Fig.2 High magnification of a large (classic) MIB-1-negative
gemistocytic cell in a gemistocytic astrocytoma (case 2). GFAP/
MIB-1 double labeling, × 1,000
Fig.3 Astrocytoma grade 4 (case 15) stained for GFAP and MIB-
1. MIB-1-immunolabeled nuclei (brown) are found in the anaplas-
tic parts, while only sporadically MIB-1-positive nuclei are seen in
the GFAP-rich (red) gemistocytic parts. GFAP/MIB-1 double la-
beling, × 150
Fig.4 Astrocytoma grade 3 (case 11) stained for GFAP and MIB-
1. Gemistocytic cells remain negative for MIB-1 immunostaining.
GFAP/MIB-1 double labeling, × 150
Fig.5 Oligodendroglioma grade 2 (case 30) stained for GFAP and
MIB-1. Whereas some MIB-1-positive nuclei of neoplastic oligo-
dendrocytes are observed, no immunoreactivity of nuclei of gemis-
tocytic cells is seen. GFAP/MIB-1 double labeling, × 150
Fig.6 The term “minigemistocytoma” was applied to oligoden-
drogliomas that are almost entirely composed of minigemistocytes
[7]. None of the minigemistocytes were immunopositive for MIB-
1 (case 31). GFAP/MIB-1 double labeling, × 150
Fig.7 Gliofibrillary oligodendrocytes (GFOCs) and minigemisto-
cytes in an oligodendroglioma (case 31). The GFOCs have a small
GFAP-positive rim around their nuclei (arrows). The minigemis-
tocytes are characterized by a more voluminous GFAP-positive
cytoplasm. Although the former occasionally show MIB-1 positiv-
ity, the minigemistocytes invariably were immunonegative for
MIB-1. GFAP/MIB-1 double labeling, × 1,000
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Fig. 8 Minigemistocytes (arrows) and GFOCs in an oligoden-
droglioma (case 31). None of the gemistocytic cells show prolifer-
ative activity, while MIB-1 immunoreactivity in nuclei of neoplas-
tic oligodendrocytes is occasionally present. GFAP/MIB-1 double
labeling, × 1,000
Fig. 9 Monstrous cell (arrow) in a monstrocellular glioblastoma
with positive MIB-1 staining in its nuclei (case 19). GFAP/MIB-1
double labeling, × 400
Fig. 10 In contrast to the monstrous cell in Fig. 9, this multinu-
clear giant cell (arrow) did not stain for MIB-1 (case 20). GFAP/
MIB-1 double labeling, × 150
PBS, MIB-1 antibody (Immunotech, Marseille, France; mouse
monoclonal, diluted 1:100 in PBS) was incubated for 2 h at RT.
After rinsing in PBS, the sections were subsequently incubated
with unconjugated goat anti-mouse antibody (Dako, The Nether-
lands), diluted 1:50 in PBS for 30 min, mouse PAP complex
(Sigma), diluted 1:300 in PBS for 30 min and 3,3’-diaminobenzi-
dine tetrahydrochloride (Fluka, Germany) for 7 min at RT. Be-
tween each incubation step the sections were rinsed three times in
PBS. Finally, a short counterstaining with hematoxylin was per-
formed. Adjacent slides of each tumor were immunostained fol-
lowing the MIB-1 protocol only.
Scoring MIB-1 LI
The MIB-1 positive nuclei were counted in five selected fields of
highest cell density, and the MIB-1 labeling index (LI) was estab-
lished by calculating the quotient of positive nuclei by total num-
ber of nuclei.
Results
Large gemistocytic cells and minigemistocytes were
found in astrocytic and oligodendroglial tumors (Table 1).
The GFOCs were only seen in the oligodendroglial and
mixed neoplasms. The numbers of these different cell
types found in each glioma were estimated (Table 1). The
cytoplasm of all astrocytic tumor cells and all gemisto-
cytic cells stained positively for GFAP. The minigemisto-
cytes and classic gemistocytes were easily detected by
their ample GFAP-positive cytoplasm, while GFOCs were
recognized by a small perinuclear GFAP-positive cyto-
plasmic rim.
MIB-1-immunoreactive cells showed a granular nu-
clear staining pattern. Similar percentages of MIB-1-la-
beled nuclei were found in sections only immunostained
for MIB-1 as compared to corresponding sections that
were double labeled with MIB-1 and GFAP. No cytoplas-
mic staining was seen. MIB-1-positive nuclei were found
in all tumors and were almost absent in the cases of reac-
tive gliosis. There were large regional differences with re-
spect to the MIB-1 immunoreactivity within the same tu-
mor samples (Fig. 1). Neoplastic astrocytes and oligoden-
drocytes often had positive nuclei (Figs. 1–10). The per-
centages of MIB-1-positive nuclei were highest in the
glioblastomas and lowest in the gliomas of lowest malig-
nancy grades (Table 1). Small anaplastic glial cells
showed the highest labeling index (Figs. 3, 10).
None of the gemistocytic cells showed positive nuclear
immunostaining (Figs. 1–10). The high labeling indices of
gemistocytic astrocytomas are a result of MIB-1 labeling
of the small anaplastic cells that were interspersed be-
tween the MIB-1-negative gemistocytes (Table 1; Figs. 1,
2). Nuclei of minigemistocytes, identified by their reactiv-
ity with anti-GFAP antibody, were never MIB-1 im-
munostained (Figs. 5–8). Some of the GFOCs were MIB-1
positive (Fig. 7). Nuclei of giant and monstrous cells
showed variable immunostaining, ranging from entirely
negative to occasionally positive (Table 1; Figs. 9, 10).
Discussion
Gemistocytic cells are well known to appear in a variety
of reactive conditions including hypoxia or ischemia.
Gemistocytes found in glial neoplasms may be interpreted
as entrapped non-neoplastic glial cells that were trans-
formed into the gemistocytic phenotype due to depriva-
tion of nutrients caused by the increasing demands of sur-
rounding tumor cells [8]. Alternatively, if regarded as a
true tumor cell, the taxonomy of the gemistocyte is uncer-
tain. On the one hand, gemistocytes seem to be related to
the non-proliferating monstrous and giant cells residing in
some high-grade gliomas [18]. On the other hand, a kin-
ship between gemistocytes and transitional cells (i.e.,
minigemistocytes and GFOCs) has been hypothesized [7].
It may be that, similar to neoplastic astrocytes, neoplastic
oligodendrocytes also metamorphose into large gemisto-
cytes, possibly via the phenotypes of GFOCs and mini-
gemistocytes. Whereas no differences in biological be-
havior of oligodendroglial tumors with or without transi-
tional cells were found, survival times of patients were
negatively affected by the presence of large gemistocytes
in tumor samples [10]. However, the finding of negative
immunostaining for MIB-1 of gemistocytes proves that
correlation of the presence of these cells with short sur-
vival is not due to proliferation of gemistocytes them-
selves, but rather to unknown factors associated with their
presence.
Although regional differences in histopathology of
glial neoplasms have been the subject of various studies
[1, 2, 4, 6, 19, 20], only a few papers concerning cell pro-
liferation in gliomas specifically address subsets of glial
cells such as gemistocytes. In early in vivo thymidine-la-
beling studies, it was shown that incorporation in gemis-
tocytes was only found in autopsy specimens acquired af-
ter variable survival times. Therefore, a gradual transfor-
mation of fibrillary and protoplasmic astrocytes into
gemistocytic cells was suggested [8]. In subsequent in
vivo studies on cell proliferation using bromodeoxyuri-
dine analogues no overall differences in labeling between
tumors with or without gemistocytes were shown [14].
The present results, however, illustrate that the high MIB-
1 LI in gemistocytic astrocytomas is a result of immunos-
taining of nuclei of cells other than the gemistocytes, a
finding that was recently confirmed by a comparative
study on intratumoral differences in cell proliferation us-
ing an incorporation technique in addition to immunohis-
tochemistry [19].
Classic gemistocytes are considered as inert cells ap-
pearing relatively late in tumor development [7, 8, 10,
13]. The present results underline the lack of proliferative
capacity of both gemistocytes and minigemistocytes. The
acquisition of GFAP-positive intermediate filaments of
neoplastic oligodendrocytes might be the first step to-
wards the non-proliferative gemistocytic cell pool, ex-
plaining diminished immunostaining for MIB-1 of the
GFOCs as compared to their GFAP-negative counterparts.
While incorporation techniques eventually show a meta-
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morphosis of one cell type into another, unfortunately no
conclusions concerning putative transformation of glial
phenotypes are possible, based on immunohistochemical
studies.
Recently, the expression of fibroblast growth factor
(FGF) has been specifically linked to gemistocytic cells
[15, 21, 25]. Both acidic and basic FGF are angiogenic
factors capable of stimulating proliferation and motility of
endothelial cells, and are mitogenic for endothelial and
glial cells. Acidic FGF was abundantly present in the cy-
toplasm of protoplasmic and gemistocytic astrocytes in
particular, while contradictory results as to the cellular
subsets expressing basic FGF were reported [21, 25]. It
has been speculated that large quantities of FGF liberated
from less-viable glial cells like gemistocytes could induce
proliferation of adjacent vascular and glial tumor cells
[21]. Further investigations on the characterization of pat-
terns of expression of growth factors and their receptors
might further specify the role of gemistocytic cells in the
biological behavior of glial neoplasms.
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